Loading metrics Open Access Peer-reviewed Research Article Citation: Schottdorf M, Rich PD, Diamanti EM, Lin A, Tafazoli S, Nieh EH, et al. (2025) TWINKLE: An open-source two-photon microscope for teaching and research. PLoS ONE 20(2): e0318924. https://doi.org/10.1371/journal.pone.0318924 Editor: Luca Pesce, Università di Pisa: Universita degli Studi di Pisa, ITALY Received: September 24, 2024; Accepted: January 23, 2025; Published: February 13, 2025 Copyright: © 2025 Schottdorf et al.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by P. Rich
TWINKLE: An open-source two-photon microscope for teaching and research
Abstract Many laboratories use two-photon microscopy through commercial suppliers, or homemade designs of considerable complexity. The integrated nature of these systems complicates customization, troubleshooting as well as grasping the principles of two-photon microscopy. Here, we present "Twinkle": a microscope for Two-photon Imaging in Neuroscience, and Kit for Learning and Education.
Magnetic voluntary head-fixation in transgenic rats enables lifespan imaging of hippocampal neurons - Nature Communications
Abstract The precise neural mechanisms within the brain that contribute to the remarkable lifetime persistence of memory are not fully understood. Two-photon calcium imaging allows the activity of individual cells to be followed across long periods, but conventional approaches require head-fixation, which limits the type of behavior that can be studied. We present a magnetic voluntary head-fixation system that provides stable optical access to the brain during complex behavior.
Efficacy and Safety of Mirikizumab (LY3074828) in the Treatment of Moderate‐to‐Severe Plaque Psoriasis: Results from a Randomised Phase 2 Study
The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Original Article Efficacy and Safety of Mirikizumab (LY3074828) in the Treatment of Moderate‐to‐Severe Plaque Psoriasis: Results from a Randomised Phase 2 Study K.
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study
Summary Background Inhibiting interleukin (IL)‐23 in patients with psoriasis has demonstrated high levels of skin clearance. Objectives To investigate, in a phase II (AMAF; NCT02899988), multicentre, double‐blind trial, the efficacy and safety of three doses of mirikizumab (LY3074828), a p19‐directed IL‐23 antibody, vs. placebo in patients with moderate‐to‐severe plaque psoriasis.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with P.
Contact P., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack